Equities analysts predict that Radius Health Inc (NASDAQ:RDUS) will post $13.71 million in sales for the current fiscal quarter, according to Zacks Investment Research. Two analysts have provided estimates for Radius Health’s earnings. The lowest sales estimate is $10.42 million and the highest is $17.00 million. The business is scheduled to issue its next earnings results on Monday, May 7th.
On average, analysts expect that Radius Health will report full year sales of $13.71 million for the current financial year, with estimates ranging from $67.66 million to $108.47 million. For the next fiscal year, analysts anticipate that the firm will report sales of $169.63 million per share, with estimates ranging from $142.94 million to $204.40 million. Zacks’ sales averages are a mean average based on a survey of sell-side research firms that cover Radius Health.
Radius Health (NASDAQ:RDUS) last announced its quarterly earnings results on Thursday, March 1st. The biopharmaceutical company reported ($1.59) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.43) by ($0.16). The business had revenue of $7.66 million for the quarter, compared to analysts’ expectations of $7.37 million. The firm’s quarterly revenue was up 666.0% compared to the same quarter last year. During the same quarter last year, the business posted ($1.22) earnings per share.
A number of research analysts have weighed in on the stock. Morgan Stanley lifted their price target on shares of Radius Health from $57.00 to $61.00 and gave the company an “overweight” rating in a research report on Friday, March 2nd. JPMorgan Chase & Co. reduced their price target on shares of Radius Health from $70.00 to $60.00 and set an “overweight” rating on the stock in a research report on Monday, February 12th. Citigroup reaffirmed a “hold” rating and set a $43.00 price target on shares of Radius Health in a research report on Monday, January 22nd. Cantor Fitzgerald reaffirmed a “buy” rating and set a $58.00 price target on shares of Radius Health in a research report on Thursday, January 18th. Finally, BidaskClub raised shares of Radius Health from a “sell” rating to a “hold” rating in a research report on Wednesday, January 10th. One research analyst has rated the stock with a sell rating, six have given a hold rating and six have given a buy rating to the company’s stock. The company presently has a consensus rating of “Hold” and an average target price of $52.22.
Shares of Radius Health (NASDAQ:RDUS) traded up $0.54 during mid-day trading on Wednesday, reaching $35.93. 592,240 shares of the company’s stock were exchanged, compared to its average volume of 1,001,635. The firm has a market capitalization of $1,595.26, a PE ratio of -6.19 and a beta of 1.19. The company has a current ratio of 5.04, a quick ratio of 4.96 and a debt-to-equity ratio of 0.69. Radius Health has a 1 year low of $24.66 and a 1 year high of $49.16.
In other news, major shareholder Growth N. V. Biotech bought 80,000 shares of Radius Health stock in a transaction dated Friday, March 2nd. The shares were acquired at an average cost of $32.52 per share, with a total value of $2,601,600.00. Following the completion of the transaction, the insider now owns 5,853,799 shares in the company, valued at approximately $190,365,543.48. The purchase was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, major shareholder Growth N. V. Biotech bought 75,000 shares of Radius Health stock in a transaction dated Friday, February 9th. The shares were purchased at an average cost of $34.38 per share, for a total transaction of $2,578,500.00. Following the completion of the transaction, the insider now owns 5,773,799 shares of the company’s stock, valued at approximately $198,503,209.62. The disclosure for this purchase can be found here. Insiders own 15.00% of the company’s stock.
Hedge funds and other institutional investors have recently bought and sold shares of the company. Cubist Systematic Strategies LLC acquired a new position in shares of Radius Health during the third quarter worth $110,000. Daiwa Securities Group Inc. acquired a new position in shares of Radius Health during the third quarter worth $385,000. Jane Street Group LLC increased its stake in shares of Radius Health by 24.7% in the fourth quarter. Jane Street Group LLC now owns 10,043 shares of the biopharmaceutical company’s stock worth $319,000 after buying an additional 1,988 shares during the last quarter. MANA Advisors LLC bought a new stake in shares of Radius Health in the fourth quarter worth $347,000. Finally, Teacher Retirement System of Texas bought a new stake in shares of Radius Health in the fourth quarter worth $353,000.
COPYRIGHT VIOLATION WARNING: “$13.71 Million in Sales Expected for Radius Health Inc (RDUS) This Quarter” was first published by Stock Observer and is owned by of Stock Observer. If you are reading this piece on another domain, it was illegally copied and republished in violation of international trademark and copyright legislation. The legal version of this piece can be viewed at https://www.thestockobserver.com/2018/03/17/13-71-million-in-sales-expected-for-radius-health-inc-rdus-this-quarter.html.
Radius Health Company Profile
Radius Health, Inc is a biopharmaceutical company. The Company is focused on the developing therapeutics in the areas of osteoporosis, oncology and endocrine diseases. The Company’s lead investigational product candidate, TYMLOS (abaloparatide-SC) injection is developed for the treatment of postmenopausal women with osteoporosis at high risk for fracture.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Radius Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Radius Health and related companies with MarketBeat.com's FREE daily email newsletter.